New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.
Updated findings from the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents provided.1
The research, published in the Journal of Clinical Oncology, includes the largest data set ever compiled on patients with tumors that have progressed on 1 or more standard treatments, or with rare cancers for which there is no standard treatment.
“The 6000-patient analysis from NCI-MATCH describes the genetic complexity that is characteristic of relapsed, refractory cancers,” Peter J. O’Dwyer, MD, a medical oncologist at the University of Pennsylvania and group co-chair of the ECOG-ACRIN Cancer Research Group, said in a press release.2 “This publication represents an important milestone in the oncology field’s efforts to translate a genetic understanding of cancer into improved treatments.”
In an interview with CancerNetwork®, lead author Keith T. Flaherty, MD, a medical oncologist at Massachusetts General Hospital Cancer Center in Boston, discussed the study findings and what NCI-MATCH will be evaluating moving forward.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
1. Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of the National Cancer Institute. doi: 10.1200/JCO.19.03010
2. Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks [news release]. Philadelphia. Published October 13, 2020. Accessed October 14, 2020. https://ecog-acrin.org/news-and-info/press-releases/genomic-study-of-6000-nci-match-cancer-patients-leads-to-new-clinical-trial-benchmarks